CY1894A - Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof - Google Patents

Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof

Info

Publication number
CY1894A
CY1894A CY189490A CY189490A CY1894A CY 1894 A CY1894 A CY 1894A CY 189490 A CY189490 A CY 189490A CY 189490 A CY189490 A CY 189490A CY 1894 A CY1894 A CY 1894A
Authority
CY
Cyprus
Prior art keywords
salts
amino
hydroxybutylidene
preparing
bisphosphonic acid
Prior art date
Application number
CY189490A
Other languages
English (en)
Inventor
Gerald R Kieczykowski
David G Melillo
Ronald B Jobson
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23431886&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1894(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of CY1894A publication Critical patent/CY1894A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Seasonings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
CY189490A 1989-06-09 1990-06-08 Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof CY1894A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/363,820 US4922007A (en) 1989-06-09 1989-06-09 Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof

Publications (1)

Publication Number Publication Date
CY1894A true CY1894A (en) 1990-06-08

Family

ID=23431886

Family Applications (1)

Application Number Title Priority Date Filing Date
CY189490A CY1894A (en) 1989-06-09 1990-06-08 Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof

Country Status (23)

Country Link
US (1) US4922007A (ko)
EP (1) EP0402152B1 (ko)
JP (2) JPH0662651B2 (ko)
KR (1) KR0137455B1 (ko)
AT (1) ATE129713T1 (ko)
AU (1) AU625704C (ko)
CA (1) CA2018477C (ko)
CH (1) CH0402152H1 (ko)
CY (1) CY1894A (ko)
DE (1) DE69023280T2 (ko)
DK (1) DK0402152T3 (ko)
ES (1) ES2080116T3 (ko)
FI (1) FI93219C (ko)
GR (1) GR3018379T3 (ko)
HK (1) HK69596A (ko)
HU (1) HU211908A9 (ko)
IE (1) IE69564B1 (ko)
IL (1) IL94612A (ko)
LV (1) LV11472B (ko)
NO (2) NO177997C (ko)
NZ (1) NZ233972A (ko)
PT (1) PT94306B (ko)
ZA (1) ZA904446B (ko)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356887A (en) * 1990-01-31 1994-10-18 Merck & Co., Inc. Pharmaceutical compositions containing insoluble calcium salts of amino-hydroxybutylidene bisphoshonic acids
US5019651A (en) * 1990-06-20 1991-05-28 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
US5159108A (en) * 1990-09-18 1992-10-27 Merck & Co., Inc. Process for preparing an antihypercalcemic agent
US5039819A (en) * 1990-09-18 1991-08-13 Merck & Co., Inc. Diphosphonate intermediate for preparing an antihypercalcemic agent
US5763611A (en) * 1992-05-29 1998-06-09 The Procter & Gamble Company Thio-substituted cyclic phosphonate compounds, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism
SG47603A1 (en) * 1992-05-29 1998-04-17 Procter & Gamble Pharma Thio-substitute nitrogen containing heterocyclic phosphonate compounds for treating abnormal calcium and phosphate metabolism
JPH07507315A (ja) * 1992-05-29 1995-08-10 プロクター、エンド、ギャンブル、ファーマスーティカルズ、インコーポレーテッド カルシウムおよびホスフェート代謝異常治療用含硫ホスホネート化合物
US5391743A (en) * 1992-05-29 1995-02-21 Procter & Gamble Pharmaceuticals, Inc. Quaternary nitrogen-containing phosphonate compounds, pharmaceutical compositions, and methods of treating abnormal calcium and phosphate metabolism and methods of treating and preventing dental calculus and plaque
CZ297094A3 (en) * 1992-05-29 1995-12-13 Procter & Gamble Pharma Phosphate compounds containing quaternary nitrogen, their use and pharmaceutical compositions containing thereof
US5753634A (en) * 1992-05-29 1998-05-19 The Procter & Gamble Company Quaternary nitrogen containing phosphonate compounds, pharmaceutical compostions, and methods for treating abnormal calcium and phosphate metabolism
FR2694558B1 (fr) * 1992-08-05 1994-10-28 Sanofi Elf Monohydrate du sel disodique de l'acide 4-chlorophénylthiométhylène bisphosphonique, sa préparation, les compositions pharmaceutiques en contenant.
US6406714B1 (en) 1992-12-02 2002-06-18 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids
US6399592B1 (en) 1992-12-23 2002-06-04 Merck & Co., Inc. Bishphosphonate/estrogen synergistic therapy for treating and preventing bone loss
FR2703590B1 (fr) * 1993-04-05 1995-06-30 Sanofi Elf Utilisation de derives d'acide bisphosphonique pour la preparation de medicaments destines a favoriser la reparation osseuse .
TW257765B (ko) * 1993-08-25 1995-09-21 Merck & Co Inc
US5510517A (en) * 1993-08-25 1996-04-23 Merck & Co., Inc. Process for producing N-amino-1-hydroxy-alkylidene-1,1-bisphosphonic acids
US5854227A (en) * 1994-03-04 1998-12-29 Hartmann; John F. Therapeutic derivatives of diphosphonates
US20010007863A1 (en) * 1998-06-18 2001-07-12 Merck & Co., Inc. Wet granulation formulation for bisphosphonic acids
US5462932A (en) * 1994-05-17 1995-10-31 Merck & Co., Inc. Oral liquid alendronate formulations
US5449819A (en) * 1994-06-06 1995-09-12 Merck & Co., Inc. Process for removing waste pox, alendronate and its by products
US5589691A (en) * 1994-06-06 1996-12-31 Merck & Co., Inc. Process for recovery and recycle of methanesulfonic acid and phosphorous acid
US5780455A (en) * 1994-08-24 1998-07-14 Merck & Co., Inc. Intravenous alendronate formulations
EP0809502A4 (en) * 1995-02-17 2001-12-05 Merck & Co Inc PROCESS FOR REDUCING THE RISK OF BONE FRACTURES OTHER THAN VERTEBRAL FRACTURES
EP0824341A4 (en) * 1995-05-12 1999-07-07 Merck & Co Inc PREVENTING TOOTH LOSS THROUGH ADMINISTRATION OF ALENDRONATE OR ITS SALTS
EP0831756A1 (en) 1995-06-06 1998-04-01 Merck & Co., Inc. Bisphosphonate cement composition to prevent aseptic loosening of orthopedic implant devices
ATE289199T1 (de) * 1995-06-06 2005-03-15 Merck & Co Inc Formulierungen mit dem wasserfreien mononatriumsalz von alendronat und deren verwendung zur behandlung von knochenkrankheiten
EP0837863A4 (en) * 1995-06-06 1999-06-16 Merck & Co Inc DISODIUM ALENDRONATE PREPARATIONS
AU723357B2 (en) * 1996-10-04 2000-08-24 Merck & Co., Inc. Liquid alendronate formulations
JP2824453B2 (ja) * 1996-10-15 1998-11-11 株式会社ワカ製作所 コネクター
CA2197267C (en) * 1997-02-11 2000-02-08 Yong Tao Process for the production of 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
IL122009A0 (en) * 1997-10-21 1998-03-10 Unipharm Ltd Salt of a bisphosphonic acid derivative
US6432931B1 (en) 1998-06-24 2002-08-13 Merck & Co., Inc. Compositions and methods for inhibiting bone resorption
US20030078211A1 (en) * 1998-06-24 2003-04-24 Merck & Co., Inc. Compositions and methods for inhibiting bone resorption
US6008207A (en) * 1998-08-13 1999-12-28 Merck & Co., Inc. Anhydrous alendronate monosodium salt formulations
EP1702924A3 (en) * 1998-08-27 2007-07-18 Teva Pharmaceutical Industries Ltd Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
RO122854B1 (ro) * 1998-08-27 2010-03-30 Teva Pharmaceutical Industries Ltd. Alendronat de sodiu hidrat, procedeu de obţinere şi compoziţie farmaceutică
US6331533B1 (en) 1998-11-16 2001-12-18 Merck & Co., Inc. Method for inhibiting dental resorptive lesions
US6160165A (en) * 1998-12-10 2000-12-12 Aesgen, Inc. Method for preparation of disodium pamidronate
US6794536B1 (en) 1998-12-10 2004-09-21 Aesqen, Inc. Method for preparation of disodium pamidronate
US6963008B2 (en) * 1999-07-19 2005-11-08 Teva Pharmaceutical Industries Ltd. Hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
ES2153794B1 (es) * 1999-08-06 2001-10-16 Medichem Sa Procedimiento para la obtencion del acido 4-amino-1-hidroxibutiliden-1,1-bisfosfonico y de su sal monosodica trihidratada.
AR021347A1 (es) 1999-10-20 2002-07-17 Cipla Ltd Una composicion farmaceutica que contiene acido(s) bisfosfoncio o sal(es) del mismo y un proceso de preparacion de la misma
AU7902800A (en) * 1999-10-26 2001-05-08 A/S Gea Farmaceutisk Fabrik Novel salts of 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid, their preparation and use
US6476006B2 (en) 2000-06-23 2002-11-05 Teva Pharmaceutical Industries, Ltd. Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
US20060269602A1 (en) * 2001-04-13 2006-11-30 Dasch James R Method of modifying the release profile of sustained release compositions
US6558702B2 (en) 2001-04-13 2003-05-06 Alkermes Controlled Therapeutics, Inc. Method of modifying the release profile of sustained release compositions
CA2372450A1 (en) * 2001-05-10 2001-09-19 Pharmaceutical Partners Of Canada Inc. Liquid injectable formulation of disodium pamidronate
TR200101250A2 (tr) * 2001-05-10 2003-04-21 E�S Eczaciba�I �Zg�N K�Myasal �R�Nler Sanay� A.�. 4-amino-1-hidroksibutiliden-1,1-bifosfonik asit veya tuzlarının hazırlanmasına ilişkin proses
GB2383042A (en) * 2001-10-18 2003-06-18 Cipla Ltd Amorphous alendronate sodium
WO2003055496A1 (en) * 2001-12-21 2003-07-10 The Procter & Gamble Company Method for the treatment of bone disorders
US20050070504A1 (en) * 2001-12-21 2005-03-31 The Procter & Gamble Co. Risedronate compositions and their methods of use
CA2472578A1 (en) * 2002-01-24 2003-07-31 Yissum Research Development Company Of The Hebrew University Of Jerusalem Anti-cancer combination and use thereof
ITMI20020146A1 (it) * 2002-01-29 2003-07-29 Lyogen Ltd Alendronato monosodico amorfo e processo per la sua preparazione
ITMI20020908A1 (it) * 2002-04-29 2003-10-29 Chemi Spa Processo di preparazione di sodio alendronato
KR20120065435A (ko) * 2002-05-10 2012-06-20 에프. 호프만-라 로슈 아게 골다공증 치료 및 예방용 비스포스폰산
ATE461205T1 (de) * 2002-05-17 2010-04-15 Teva Pharma Verwendung von bestimmten lösungsmitteln zur herstellung von bisphosphonsäuren
JP2005534653A (ja) * 2002-06-06 2005-11-17 メルク フロスト カナダ アンド カンパニー 眼及び骨疾患の治療に於いてｅｐ４受容体作動薬として使用するための１，５−二置換イミダゾリジン−２−オン誘導体
JP4485117B2 (ja) * 2002-06-27 2010-06-16 日東電工株式会社 保護剥離用フィルム
EP1545517A1 (en) * 2002-08-28 2005-06-29 Merck Frosst Canada & Co. Oxazolidin-2-one and thiazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of glaucoma
US20040138180A1 (en) * 2002-10-03 2004-07-15 Barr Laboratories, Inc. Bisphosphonate composition and process for the preparation thereof
BR0309691A (pt) * 2002-12-20 2005-08-02 Hoffmann La Roche Formulação de ibandronato em alta dose
US20040206932A1 (en) * 2002-12-30 2004-10-21 Abuelyaman Ahmed S. Compositions including polymerizable bisphosphonic acids and methods
HUP0300227A2 (hu) * 2003-01-28 2004-09-28 Richter Gedeon Vegyészeti Gyár Rt. Eljárás nagy tisztaságú 2-szubsztituált -1-(hidroxi-etilidén)-1,1-biszfoszfonsavak és sóik előállítására
WO2005018581A2 (en) * 2003-08-12 2005-03-03 3M Innovative Properties Company Self-etching dental compositions and methods
US7411087B2 (en) * 2003-08-21 2008-08-12 Sun Pharmaceutical Industries Limited Process for preparation of bisphosphonic acid compounds
EP1673336B1 (en) 2003-08-21 2014-06-04 Merck Canada Inc. Cathepsin cysteine protease inhibitors
CA2539359A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a bisphosphonate
WO2005035542A1 (en) * 2003-10-14 2005-04-21 Pliva-Istrazivanje I Razvoj D.O.O. Solid-state form of alendronate sodium and preparation thereof
US20050261250A1 (en) * 2004-05-19 2005-11-24 Merck & Co., Inc., Compositions and methods for inhibiting bone resorption
KR20080083068A (ko) 2004-05-24 2008-09-12 더 프록터 앤드 갬블 캄파니 킬레이팅제를 함유하는 비스포스포네이트의 고형의 장용 경구 투여 형태
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
CA2573020A1 (en) * 2004-07-08 2006-02-09 3M Innovative Properties Company Dental methods, compositions, and kits including acid-sensitive dyes
EP1784155B1 (en) * 2004-08-11 2011-09-28 3M Innovative Properties Company Self-adhesive compositions including a plurality of acidic compounds
US7361761B2 (en) * 2004-09-28 2008-04-22 Orchid Chemicals & Pharmaceuticals Ltd. Process for the preparation of bisphosphonic acid
US7214818B2 (en) 2004-10-29 2007-05-08 Hoffmann-La Roche Inc. Method for synthesizing bisphosphonate
CN1304401C (zh) * 2004-12-28 2007-03-14 浙江工业大学 一种阿伦膦酸的制备方法
EP1855674B1 (en) 2005-03-02 2014-07-16 Merck Sharp & Dohme Corp. Composition for inhibition of cathepsin k
BRPI0606280A2 (pt) * 2005-03-17 2009-06-09 Elan Pharma Int Ltd composições de bisfosfonato nanoparticulado
EP1891081B1 (en) * 2005-06-13 2014-08-20 Jubilant Organosys Limited Process for producing bisphosphonic acids and forms thereof
AR054673A1 (es) 2005-07-28 2007-07-11 Gador Sa Una forma cristalina del acido zoledronico, un proceso para su obtencion y la composicion farmaceutica que la comprende
US8003820B2 (en) * 2005-10-20 2011-08-23 Dr. Reddy's Laboratories Limited Process for preparing bisphosphonic acids
BRPI0618100B1 (pt) 2005-10-31 2018-03-27 Cabot Corporation Corantes modificados e composições de tinta para jatos de tinta compreendendo corantes modificados
ES2323728T3 (es) 2005-12-27 2009-07-23 Ipca Laboratories Limited Proceso mejorado para la fabricacion de 4-amino-hidroxibutilideno-1,1-bisfosfonico y sus sales.
WO2007083240A2 (en) 2006-01-20 2007-07-26 Aurobindo Pharma Limited An improved process for the preparation of bisphosphonic acids
CA2570949A1 (en) * 2006-12-12 2008-06-12 Apotex Pharmachem Inc. Ibandronate sodium propylene glycol solvate and processes for the preparation thereof
EP2101716A2 (en) 2006-12-13 2009-09-23 3M Innovative Properties Company Methods of using a dental composition having an acidic component and a photobleachable dye
BRPI0809548A8 (pt) 2007-04-11 2018-10-16 Hoffmann La Roche processo para a preparação do sal ácido- (mono-hidratado)-3- (n-metil-n-pentil) amino-1-hidroxipropano-1, 1-difosfônico monossódico
WO2008157050A1 (en) * 2007-06-19 2008-12-24 Albemarle Corporation Processes for manufacturing bisphosphonic acids
WO2009050731A2 (en) * 2007-06-20 2009-04-23 Alkem Laboratories Ltd Novel process for preparing risedronic acid
US20090170815A1 (en) * 2007-12-28 2009-07-02 Roxane Laboratories Incorporated. Alendronate oral liquid formulations
US20090197837A1 (en) * 2008-02-05 2009-08-06 Desai Vivek S Alendronate formulations, method of making and method of use thereof
US8026388B2 (en) * 2008-07-11 2011-09-27 Synthon Bv Process for making 1-hydroxyalkylidene-1,1-biphosphonic acids
US20100130746A1 (en) * 2008-11-26 2010-05-27 Martin Kas Process for Making Zoledronic Acid
US20120100206A1 (en) 2009-06-11 2012-04-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Targeted liposomes comprising n-containing bisphosphonates and uses thereof
EA201270328A1 (ru) 2009-08-28 2012-09-28 Синтон Б. В. Способ получения 1-гидроксиалкилиден-1,1-дифосфоновых кислот
EP2484727A4 (en) 2009-09-30 2014-08-20 Dainippon Printing Co Ltd Ink Composition
CA2738045C (en) 2010-05-28 2019-02-19 Simon Fraser University Conjugate compounds, methods of making same, and uses thereof
EP2609101B1 (en) 2010-07-14 2015-01-28 Pharmathen S.A. Process for the preparation of 3-(n-methyl-n-pentyl)amino-1-hydroxypropane-1,1-diphosphonic acid salt or derivatives thereof
EP2598587B1 (en) 2010-07-30 2018-12-19 Cabot Corporation Polymeric pigment systems and methods
BR112013010476B1 (pt) 2010-12-06 2021-07-06 Effrx Pharmaceuticals Sa formulações efervescentes estáveis de bisfosfonato com características de solubilização rápida
CN103298620B (zh) 2010-12-27 2015-05-06 Dnp精细化工有限公司 喷墨记录方法
EP2675440B1 (en) 2011-02-14 2020-03-25 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
EP2692537B1 (en) 2011-03-29 2016-06-22 DNP Fine Chemicals Co., Ltd. Inkjet recording method and ink set for inkjet recording
PL2731591T3 (pl) 2011-07-13 2021-05-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Liposomy zawierające bisfosfonian i środek amfipatyczny w wyniku ko-enkapsulacji
GB201200868D0 (en) 2012-01-19 2012-02-29 Depuy Int Ltd Bone filler composition
JP5722860B2 (ja) 2012-10-11 2015-05-27 株式会社Ｄｎｐファインケミカル 水性インクジェット受理溶液、この受理溶液を含むインクセット及びこのインクセットを用いたインクジェット記録方法
WO2015051479A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
CN105593230B (zh) 2013-10-08 2018-07-06 默沙东公司 组织蛋白酶半胱氨酸蛋白酶抑制剂
JP5779630B2 (ja) 2013-11-27 2015-09-16 株式会社Ｄｎｐファインケミカル インクジェット記録用インク組成物、及びその製造方法、並びに、インクジェット記録方法
JP5676734B1 (ja) 2013-12-27 2015-02-25 株式会社Ｄｎｐファインケミカル インクジェット記録用インク組成物、インクジェット記録方法、及び印刷物の製造方法
WO2015120580A1 (en) 2014-02-11 2015-08-20 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
PL407922A1 (pl) 2014-04-16 2015-10-26 Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Odpowiedzialnością Nowe bisfosfoniany i ich zastosowanie
US9650414B1 (en) 2014-05-30 2017-05-16 Simon Fraser University Dual-action EP4 agonist—bisphosphonate conjugates and uses thereof
KR20160147007A (ko) 2014-05-30 2016-12-21 화이자 인코포레이티드 선택적인 안드로겐 수용체 조절제로서의 카보니트릴 유도체
CN104072538A (zh) * 2014-07-10 2014-10-01 陕西汉江药业集团股份有限公司 一种双膦酸盐类药物的合成方法
CN107849072B (zh) 2015-06-12 2020-12-15 西蒙弗雷泽大学 酰胺连接的ep4激动剂-二膦酸盐化合物及其用途
EP3827010A4 (en) 2018-07-23 2022-03-16 Brise Pharmaceuticals Co., Ltd. BISPHOSPHONATE-DRUG CONJUGATES
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2534391C2 (de) * 1975-08-01 1983-01-13 Henkel KGaA, 4000 Düsseldorf 1-Hydroxy-3-aminoalkan-1,1-diphosphonsäuren
DE2745083C2 (de) * 1977-10-07 1985-05-02 Henkel KGaA, 4000 Düsseldorf Hydroxydiphosphonsäuren und Verfahren zu deren Herstellung
DE2943498C2 (de) * 1979-10-27 1983-01-27 Henkel KGaA, 4000 Düsseldorf Verfahren zur Herstellung von 3-Amino-1-hydroxypropan-1,1-diphosphonsäure
DE3016289A1 (de) * 1980-04-28 1981-10-29 Henkel KGaA, 4000 Düsseldorf Verfahren zur herstellung von omega -amino-1-hydroxyalkyliden-1,1-bis-phosphonsaeuren
US4304734A (en) * 1980-10-16 1981-12-08 Vysoka Skola Chemicko-Technologicka 6-Amino-1-hydroxyhexylidene diphosphonic acid, salts and a process for production thereof
IT1201087B (it) * 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
US4639338A (en) * 1984-08-06 1987-01-27 Ciba-Geigy Corporation Preparation of crystalline disodium 3-amino-1-hydroxypropane-1,1-diphosphonate pentahydrate
IT1196315B (it) * 1984-10-29 1988-11-16 Gentili Ist Spa Procedimento per la preparazione di acidi difosfonici

Also Published As

Publication number Publication date
NO178228C (no) 1996-02-14
HU211908A9 (en) 1996-01-29
CA2018477A1 (en) 1990-12-09
LV11472A (lv) 1996-08-20
DE69023280D1 (de) 1995-12-07
JPH0662651B2 (ja) 1994-08-17
CA2018477C (en) 1995-08-01
ZA904446B (en) 1992-06-24
NO902559L (no) 1990-12-10
IE69564B1 (en) 1996-10-02
LV11472B (en) 1996-12-20
PT94306B (pt) 1997-05-28
IL94612A (en) 1995-03-30
NZ233972A (en) 1992-05-26
IL94612A0 (en) 1991-04-15
KR0137455B1 (ko) 1998-05-01
KR910000768A (ko) 1991-01-30
NO902559D0 (no) 1990-06-08
ATE129713T1 (de) 1995-11-15
JPH03101684A (ja) 1991-04-26
PT94306A (pt) 1991-02-08
NO941726D0 (no) 1994-05-09
US4922007A (en) 1990-05-01
FI902845A0 (fi) 1990-06-07
EP0402152B1 (en) 1995-11-02
CH0402152H1 (fr) 2006-02-28
FI93219B (fi) 1994-11-30
IE902073L (en) 1990-12-09
NO177997B (no) 1995-09-25
HK69596A (en) 1996-04-26
NO177997C (no) 1996-01-03
GR3018379T3 (en) 1996-03-31
ES2080116T3 (es) 1996-02-01
EP0402152A3 (en) 1991-07-03
FI93219C (fi) 1995-03-10
NO941726L (no) 1990-12-10
AU625704C (en) 2001-07-26
JPH0748391A (ja) 1995-02-21
AU5701990A (en) 1990-12-13
DK0402152T3 (da) 1995-12-04
DE69023280T2 (de) 1996-06-20
EP0402152A2 (en) 1990-12-12
AU625704B2 (en) 1992-07-16
NO178228B (no) 1995-11-06

Similar Documents

Publication Publication Date Title
CY1894A (en) Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
KR0173467B1 (en) Improved process for preparing 4-amino-1-hydroxybutylidene-1, 1-bisphosphonic acid(abp)or salts thereof
PL335053A1 (en) Method of obtaining 4-amino 1-hydroxybutylyidene-1,1-bisphosphonic acid
DK199489A (da) Fremgangsmaade til fremstilling af n-t-alkyl-1,2-diacylhydraziner
DE3067924D1 (en) A partial thromboplastine
DK0494844T3 (da) Fremgangsmåde til fremstilling af diphosphonsyre og salte deraf
DK0433846T3 (da) Fremgangsmåde til fremstilling af 2-acylamino-6-halogen-purin ud fra 2,9-diacylguanin
HUT58711A (en) Process for producing 4-amino-3-hydroxy-phtalide